Added to YB: 2026-03-04
Pitch date: 2026-03-02
BMRN [neutral]
BioMarin Pharmaceutical Inc.
-2.42%
current return
Author Info
Tensor Trader is a quantamental investor who combines value, quality, and momentum factor models with fundamental catalysts and a top-down macro view, turning messy data into clear signals. Sign up for the newsletter.
Company Info
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Market Cap
$11.9B
Pitch Price
$59.98
Price Target
86.00 (+47%)
Dividend
N/A
EV/EBITDA
14.92
P/E
34.21
EV/Sales
3.40
Sector
Biotechnology
Category
value
Quarterly Update: BioMarin Pharmaceutical (BMRN)
BMRN (update): Q4 rev $875M (+17% YoY) beat est $835M; FY25 rev $3.22B (+13% YoY). Non-GAAP EPS $0.46 missed $0.77 est on one-time Roctavian impairment. Voxzogo $927M (+26% YoY), legacy ERT $2.1B (+9%). FCF $828M (+45%). Amicus deal ($4.8B) closes Q2 2026, 3.0x net leverage deleveraging to <2.5x in 2yrs. 2026 guide: $3.33-3.43B rev, $4.95-5.15 EPS, 40% op margin target. PT $86; asymmetric risk/reward intact.
Read full article (2 min)